Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
MINNEAPOLIS, June 07, 2017 -- Sun BioPharma, Inc., (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced that David Kaysen, the Company’s Chief Executive Officer, is scheduled to present at the 2017 Marcum MicroCap Conference on Thursday, June 15, 2017 at 2:30 p.m. Eastern Time, in the Julliard room at The Grand Hyatt Hotel located at 109 East 42nd Street, New York, NY.
The presentation will be webcast live at http://wsw.com/webcast/marcum5/snbp and can also be accessed through the Company’s website at http://www.sunbiopharma.com. A replay of the presentation will be available and archived for 90 days.
Persons attending the Marcum conference who would like to schedule a 1-on-1 meeting with Sun BioPharma, Inc. management during such conference may do so by contacting David Kaysen at [email protected] or Scott Kellen at [email protected].
About Sun BioPharma
Sun BioPharma Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The Company’s development programs target diseases of the pancreas, including pancreatic cancer and pancreatitis; the Company’s initial product candidate is SBP-101 for the treatment of patients with pancreatic cancer. The Company is currently engaged in a Phase 1 dose-escalation with SBP-101. Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, the University of Miami, the University of Florida, the Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia. Further information can be found at: www.sunbiopharma.com. Sun BioPharma’s common stock is currently quoted on the OTCQB tier of the over-the-counter markets administered by the OTC Markets Group, Inc. under the symbol: SNBP.
Contact Information:
EVC Group
Investor & Media Contact:
Doug Sherk
415-652-9100
Michael Polyviou
212-850-6020
